Monte Rosa Therapeutics
Monte Rosa Therapeutics' revenue rose 63.5% to $124 million in fiscal 2025. Its operating margin was −43.8%, up from −107.3% a year earlier. Free cash flow was −$28 million, against $38 million a year earlier. The diluted share count rose 12.4%.
Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on equity is net income as a share of shareholders' equity. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.
Charts show fiscal years, from the 10-K filings.
What Monte Rosa Therapeutics does
Monte Rosa Therapeutics is a biotechnology company that tests experimental drugs in people. It has no medicines on the market. It works on small-molecule drugs called molecular glue degraders, which use the body's own system for breaking down proteins to remove a protein that drives a disease. It finds them with its own discovery platform, QuEEN, which uses artificial intelligence and lab screening.
Three programs are in clinical trials. MRT-6160 targets a protein called VAV1 for immune-mediated diseases. MRT-8102 targets NEK7 for diseases driven by inflammation, including heart disease risk. MRT-2359 targets GSPT1 for metastatic castration-resistant prostate cancer. It also has earlier programs aimed at cyclin E1 and CDK2, proteins linked to cancer.
Monte Rosa has no revenue from drug sales. In October 2024 it licensed MRT-6160 to Novartis, which handles later clinical studies. Monte Rosa received an upfront payment of $150 million and can earn milestone payments and a share of profits and losses in the United States, plus royalties outside it. It has lost money since it began and says it will need substantial additional funding.
Its biggest risks, as it describes them
- A limited operating history, no drug sales so far, and continued losses.
- Its programs are early, and its drug discovery approach is new, so cost, timing and success are hard to predict.
- Needing to raise substantial additional funding before it can finish developing any drug.
- Trouble enrolling patients in clinical trials, or failing to win regulatory approval.
- Being unable to protect its patents and other intellectual property, or to keep key staff.
Income statement
Monte Rosa Therapeutics lost money in fiscal 2025: a net loss of $39 million.
Returns on capital
Balance sheet
Five years at a glance
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | 346 | 55 | 128 | 224 | 377 |
| Debt incl. finance leases | — | — | — | — | — |
| Net debt (negative means net cash) | — | — | — | — | — |
| Net debt to EBITDA | — | — | — | — | — |
| Debt to equity | — | — | — | — | — |
| Interest coverage | — | — | — | — | — |
| Current ratio | 21.0x | 10.8x | 5.1x | 2.4x | 6.1x |
| Quick ratio | 21.0x | 10.8x | 5.1x | 2.4x | 6.1x |
Cash flow
Projections
Project Monte Rosa Therapeutics' revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.
Insider trades
No officer, director or 10% owner of Monte Rosa Therapeutics reported buying or selling its shares on the open market between November 14, 2025 and November 13, 2026.
Indicators
Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.
| Indicator | FY23 | FY24 | FY25 |
|---|---|---|---|
| Piotroski F-score | — | — | — |
| Rule of 40 | — | — | 41.3% |
| Altman Z'' | −1.49 | −0.12 | 1.67 |
| Accruals ratio | −28.3% | −30.9% | −3.6% |
The nine F-score tests
| Test | FY23 | FY24 | FY25 |
|---|---|---|---|
| Net income is positive | Fail | Fail | Fail |
| Cash from operations is positive | Fail | Pass | Fail |
| Return on assets rose | Fail | Pass | Pass |
| Cash from operations exceeds net income | Pass | Pass | Pass |
| Debt fell relative to assets | — | — | — |
| Current ratio rose | Fail | Fail | Pass |
| Share count didn't rise | Fail | Fail | Fail |
| Gross margin rose | — | — | — |
| Revenue rose relative to assets | — | Pass | Pass |
| F-score | — | — | — |
Compare
Put Monte Rosa Therapeutics side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.
Similar companies
| Company | Year | Revenue growth | Operating margin | Free cash flow margin | Return on capital | Net debt to EBITDA | F-score | Compare |
|---|---|---|---|---|---|---|---|---|
| Monte Rosa Therapeutics | FY25 | 63.5% | −43.8% | −22.2% | — | — | — | |
| Xencor | FY25 | 13.7% | −141.3% | −110.1% | −19.9% | — | 3 | Compare |
| ImmunityBio | FY25 | 668.3% | −226.0% | −272.6% | — | — | 3 | Compare |
| Beam Therapeutics | FY25 | 120.0% | −274.6% | −257.6% | — | — | — | Compare |
| Regenxbio | FY25 | 104.5% | −94.6% | −74.2% | — | — | — | Compare |
6 years of figures
| Fiscal year | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|
| Income statement | ||||||
| Revenue | — | — | — | 0 | 76 | 124 |
| Revenue growth | — | — | — | — | — | 63.5% |
| Gross profit | — | — | — | — | — | — |
| Research and development | 24 | 57 | 85 | 111 | 122 | 142 |
| Operating income | −28 | −73 | −112 | −143 | −81 | −54 |
| Net income | −36 | −74 | −108 | −135 | −73 | −39 |
| Diluted EPS (US$) | −23.65 | −2.96 | −2.30 | −2.63 | −0.98 | −0.46 |
| Diluted shares (millions) | 2 | 25 | 47 | 51 | 74 | 83 |
| Cash flow | ||||||
| Cash from operations | −23 | −59 | −92 | −44 | 42 | −23 |
| Capital expenditure | 3 | 10 | 13 | 19 | 4 | 5 |
| Free cash flow | −26 | −69 | −105 | −63 | 38 | −28 |
| Dividends paid | 0 | 0 | 0 | 0 | 0 | 0 |
| Share buybacks | 0 | 0 | 0 | 0 | 0 | 0 |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 |
| Stock-based compensation | 0 | 5 | 12 | 17 | 18 | 19 |
| Balance sheet at fiscal year end | ||||||
| Cash and short-term investments | 42 | 346 | 55 | 128 | 224 | 377 |
| Debt incl. finance leases | — | — | — | — | — | — |
| Total assets | 49 | 366 | 342 | 304 | 439 | 449 |
| Total liabilities | 30 | 19 | 71 | 124 | 216 | 216 |
| Shareholders' equity | −49 | 348 | 271 | 179 | 223 | 233 |
| Margins and ratios | ||||||
| Gross margin | — | — | — | — | — | — |
| Operating margin | — | — | — | — | −107.3% | −43.8% |
| Net margin | — | — | — | — | −96.1% | −31.2% |
| Free cash flow margin | — | — | — | — | 50.3% | −22.2% |
| Rule of 40 (growth + FCF margin) | — | — | — | — | — | 41.3% |
| Return on capital | — | — | — | — | — | — |
| Return on equity | — | −49.5% | −35.1% | −60.1% | −36.1% | −16.9% |
| Return on assets | — | −35.6% | −30.6% | −41.9% | −19.6% | −8.7% |
| Net debt to EBITDA | — | — | — | — | — | — |